This micro-blog is specifically for a discussion of equities trading in Pre-Market or After-Market, Or Extremely URGENT, verifiable News relating to Global Markets.
It may also include certain nuances in specific markets and sharing of information with others on their Standard Operating Procedures, as well as access to those markets.
Have FUN, keep it real and enjoy each others company, tidbits of advice, humor, expertise or lack thereof. The Gummunity is a Sharing and Caring environment; Please Keep It Clean.
Bes2ALL! – >>>–BenJammmin’——->
This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.
$TEUM fp > Pareteum and Artilium Announce Agreement for Pareteum to Acquire Artilium in $104.7 Million Transaction https://www.pareteum.com/news/pareteum-and-artilium-announce-agreement-for-pareteum-to-acquire-artilium-in-104-7-million-transaction/
Pareteum and Artilium Announce Agreement for Pareteum to Acquire Artilium in $104.7 Million Transaction
Pro-Forma 2018 Revenue Outlook of $49 Million
Expected to be Accretive to 2019 Earnings
Conference Call Scheduled for Friday, June 8 at 11am ET
🙂 #Best2ALL! 🙂
$TSLA Short sellers betting against Tesla lose more than $1 billion in single day as stock pops https://cnb.cx/2Lqk36O #tesla #tsla #stockstowatch #investing #trading #WallStreet #markets
#Thanks @tipranks https://twitter.com/TipRanks/status/1004614289414553600
$MDGL priced 1.34M shares at $305/Share
Thx Odi https://twitter.com/odibro/status/1004652269411979264
$FSLR $CSIQ $JKS $SPWR $SOL Billions in U.S. solar projects shelved after Trump panel tariff https://twitter.com/ACInvestorBlog/status/1004595565257256960
$TEVA $CMRE $SRRA $AETI $GALT and more. Watchlist: https://finviz.com/screener.ashx?v=211&ta=0&t=TEVA,ATNM,DARE,AETI,CMRE,EGY,HEAR,VSAR,CHK,GALT,IQ,SRRA ,CHRS,WRD,ENPH,STG … Thx BMT https://twitter.com/BioMoneyTrees/status/1004933313809838080 hear srra wow Best
$BLPH wow Form 4 x8 directors 38,216 options each @ 2.27usd Best
$BLPH WOW! > +1/4 to long position at $248 Data due June or July.
🙂 #Best2ALL! 🙂
$CLRB wow > Cellectar Granted U.S. Patent for the Treatment of Various Cancers and Cancer Stem Cells with CLR 131 https://globenewswire.com/news-release/2018/06/07/1518403/0/en/Cellectar-Granted-U-S-Patent-for-the-Treatment-of-Various-Cancers-and-Cancer-Stem-Cells-with-CLR-131.html
$CLRB FDA Grants Rare Pediatric Disease Designation to Cellectar Biosciences’ CLR 131 for the Treatment of Rhabdomyosarcoma https://globenewswire.com/news-release/2018/06/06/1517601/0/en/FDA-Grants-Rare-Pediatric-Disease-Designation-to-Cellectar-Biosciences-CLR-131-for-the-Treatment-of-Rhabdomyosarcoma.html
$TEUM WOW! > +3X at 2.24 Conference call Q&A currently either on website or toll free call. Travis, have you assessed THIS equity and transaction? 🙂 #Best2ALL! 🙂
$SMMT > Summit Therapeutics Unveils Second Novel Target for Gonorrhoea at ASM Microbe 2018
Summit Therapeutics plc
(“Summit” or the “Company”)
Summit Unveils Second Novel Target for Gonorrhoea at ASM Microbe 2018
Highlights the Power of the Discuva Platform to Identify Novel Antibiotic Targets
Oxford, UK, and Cambridge, MA, US, 11 June 2018 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) announces the discovery of a second novel target to kill the bacteria Neisseria gonorrhoeae. The new target, identified using Summit’s Discuva Platform, is distinct from that of existing antibiotics and also from Summit’s recently announced lead series of new mechanism antibiotics for gonorrhoea.
Summit also reports the discovery of a promising new series of compounds against this second target. This series of compounds have the characteristics the Company believes are required for a treatment of gonorrhoea by combining high potency with selective targeting of N. gonorrhoeae, including resistant strains.
This research was showcased as part of Summit’s presentations at the ASM Microbe 2018 congress in Atlanta, US. Summit also reported preclinical data at this congress on its lead gonorrhoea series from which it expects to nominate a candidate to advance into IND enabling studies during the second half of 2018.
“Gonorrhoea poses an urgent threat as the world approaches an era of untreatable disease due to increasing resistance against the last recommended treatment option,” commented Dr David Roblin, Summit’s President of Research and Development. “Having two novel approaches with the potential to combat gonorrhoea means Summit has an opportunity to meaningfully contribute to the fight against this significant worldwide health threat.”
Both series of compounds were identified with Summit’s Discuva Platform, a proprietary genetics-based technology for the discovery and development of new antibiotics against multiple pathogens associated with antibiotic resistance.
“We believe our Discuva Platform has the potential to radically change antibiotic drug discovery and development,” added Dr Roblin. “Gonorrhoea is the first pathogen we are targeting with our platform to bring forward new mechanism antibiotics. Exploiting new bacterial targets will be critical to ensure we are developing potential new standards of care treatments that are capable of achieving commercial success.”
Copies of all the presentations given at ASM Microbe 2018 are available in the publications section of the Company’s website, http://www.summitplc.com.
About Gonorrhoea
It is estimated by the World Health Organization (‘WHO’) that there are approximately 78 million new cases of gonorrhoea globally per year. Neisseria gonorrhoeae has consistently developed resistance to each class of antibiotics recommended for treatment and there is now only one treatment recommended by the Centers for Disease Control, a combination of two antibiotics which is approaching the point at which its use should be stopped. There are currently no other recommended antibiotics that can be effectively deployed to target the disease. The WHO ranks as “High” the priority of R&D investment into the search for antibiotics which are effective against N. gonorrhoeae.
About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications in neuromuscular and infectious diseases for which there are no existing or only inadequate therapies. Summit is currently conducting clinical programmes focused on the neuromuscular disease Duchenne muscular dystrophy and the infectious disease C. difficile infection. Further information is available at http://www.summitplc.com and Summit can be followed on Twitter (@summitplc).
Have a grand week all!
$TEUM > Pareteum Expects Second Quarter 2018 Revenue of At Least $5.75 Million
Represents a 78% Increase Over Second Quarter 2017
2018 Revenue Outlook Raised to 80% Year-Over-Year Growth
NEW YORK, NEW YORK – PRNewswire – July 10, 2018 – Pareteum Corporation (NYSE American: TEUM), (“Pareteum” or the “Company”), the rapidly growing Cloud Communications Platform company, announced today that the Company expects to report revenues of at least $5.75 million, which represents approximately 78% growth for the second quarter ended June 30, 2018, as compared to a year ago. The second quarter’s expected 2018 revenues will represent an approximate 40% sequential growth over the first quarter of 2018, demonstrating the strong growth in connections that was previously reported in the first quarter of 2018.
Connections, which are a lead indicator of revenue, rose to approximately 2,713,600 as of June 30, 2018, representing a 22.5% quarter over quarter growth in 2018. The year over year increase, from the end of the second quarter 2017 to the end of the second quarter 2018, was a significant 225%, providing management the confidence to increase its projected 2018 revenue outlook to a substantial 80% annual revenue growth over 2017’s year-end totals.
Hal Turner, Executive Chairman and Principal Executive Officer of Pareteum, commented, “Our TEUM surged into 2018 with strong first quarter results, demonstrated by the acceleration in revenues and connections. This momentum has continued into the second quarter, at an accelerating rate, because of rapid conversions of our 36 Month Contractual Revenue Backlog. We see this translating into our best quarter, ever. We anticipate continued improvement in our results and execution of our long-term strategies, aimed at open mobility and open applications, globally delivered as part of excellent customer experiences in every engagement.”
Pareteum’s second quarter, ended June 30, 2018, earnings and results update call is expected to be held during the week of August 6, 2018.
About Pareteum:
The mission of Pareteum Corporation (NYSE American: TEUM) is to connect “every person and everything.” Organizations use Pareteum to energize their growth and profitability through cloud communication services and complete turnkey solutions featuring relevant content, applications, and connectivity worldwide. Our platform services partners (technologies integrated into our cloud) include: HPE, IBM, Sonus, Oracle, Microsoft, and other world class technology providers. All of the relevant customer acquired value is derived from Pareteum’s award winning software, developed and enhanced for many years. By harnessing the value of communications, Pareteum serves retail, enterprise and IoT customers. Pareteum currently has offices in New York, Sao Paulo, Madrid, Barcelona, Bahrain and the Netherlands. For more information please visit: http://www.pareteum.com.
Forward Looking Statements:…. #Best2All! 🙂
Are you invested in this stock? TEUM?
$CAPR long > Capricor and USAISR Announce Collaboration to Investigate Exosome Platform to Treat Injured Troops
7:00 am ET July 17, 2018 (Globe Newswire) Print
Capricor Therapeutics (NASDAQ:CAPR) today announced it has entered into an agreement with the U.S. Army Institute of Surgical Research (USAISR) to study the potential for the company’s next-generation investigational therapeutic platform, designated CAP-2003, which represents extracelluar vesicles (e.g., exosomes and microvesicles) to address a wide spectrum of trauma-related injuries and conditions, which are now the third leading cause of death in the U.S.
CAP-2003 is derived from Capricor’s proprietary cardiosphere-derived cells (CDCs), which comprise adult cardiac progenitor cells from donor heart tissue. CAP-2003 has shown promising results in various pre-clinical experiments using established animal models of diseases by exerting anti-inflammatory, anti-fibrotic, pro-angiogenic, and anti-apoptotic effects.
“In developing CAP-2003, Capricor has distilled the active pharmaceutical ingredient (API) of the cells and created a therapeutic that may be easier to use than cell-based therapeutics,” said Linda Marban, Ph.D., Capricor president and CEO. “CAP-2003 doesn’t require refrigeration or special handling, potentially making it well suited for treating and stabilizing injured soldiers in the field, potentially improving their chances of surviving until they can be transported and receive treatment at medical facilities.”
USAISR entered into the collaboration with Capricor after determining cell-free therapies offer great promise for treating conditions that contribute to soldier morbidity and mortality. Capricor will provide CAP-2003 for testing of function, potency and safety for eventual use in therapeutic indications. Because this is potentially a very important clinical use of CAP-2003, Capricor will work closely with USAISR on its studies and in publishing results of those studies in peer-reviewed journals.
“We were very pleased to enter into this collaboration with Capricor and look forward to studying the utility and delivery of exosomes for trauma-related injuries that soldiers experience on the battlefield,” said James Bynum, Ph.D., USAISR principal investigator. “One of the goals of this collaboration is to test whether CAP-2003 will provide a useful tool on the battlefield to stabilize injured soldiers while they wait for transport to a medical facility. If we can achieve this goal, we will be able to potentially make a meaningful difference in the preservation of life. One of the reasons exosomes are so exciting as a potential therapeutic is their stability, which may allow them to be carried in a medic’s pack and deployed immediately. This is in contrast to earlier cell-based therapies where the necessity of a frozen product prevented easy access. This could be the beginning of a completely new therapeutic paradigm in stabilizing injured warriors.”
The exosomes produced by the CDCs are quantitatively different in terms of contents compared to mesenchymal stem cells (MSC) and other types of exosomes. Preclinical studies suggest that CAP-2003 might lead to different and perhaps augmented clinical benefit when directly compared to other types of exosomes.
“This collaboration will provide the much-needed standardization of extracellular vesicle production, usage and identification for this rapidly growing field, further positioning us as one of the leaders in the development of therapeutic exosomes,” said Dr. Marban. “This endeavor stands to open up a new arena in biotechnology, where the benefits of cells can be distilled down to the API now known to be extracellular vesicles. Our work with USAISR is also important for the further development of our CAP-2003 technology because if it proves to be promising, we will work on developing large-scale manufacturing as well as clinical development as a result of it.”
About CAP-2003
CAP-2003 is being developed as a next-generation therapeutic platform in regenerative medicine. CAP-2003 is comprised of nano-sized extracellular vesicles, including exosomes and microvesicles, which exert anti-inflammatory, pro-angiogenic, anti-apoptotic, and anti-fibrotic effects. CAP-2003 contains several characteristic lipids, proteins, and RNA molecules (e.g., microRNAs). They act as messengers to regulate the functions of neighboring cells. Pre-clinical research has shown that exogenously-administered extracellular vesicles can direct or, in some cases, re-direct cellular activity, supporting their therapeutic potential. Their size, ease of crossing cell membranes and ability to communicate in native cellular language make them an exciting class of potential therapeutic agents…. #Best2ALL! 🙂
$AXSM > Bid 204K at $3.05 Axsome Therapeutics Announces AXS-05 Presentation at the 2018 Alzheimer’s Association International Conference
Date(s): 17-Jul-2018 7:00 AM
For a complete listing of our news releases, please click here
NEW YORK, July 17, 2018 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced a poster presentation on AXS-05 at the 2018 Alzheimer’s Association International Conference (AAIC) on July 23, 2018 in Chicago, IL. AXS-05 is a novel, oral, investigational medicine consisting of dextromethorphan and bupropion, in late-stage development for the treatment of agitation associated with Alzheimer’s disease.
The presentation will highlight data correlating AXS-05 drug levels from Phase 1 trials to neurotransmitter receptor activation and to improvements in agitation symptoms in patients with Alzheimer’s disease. The current status of the Company’s ongoing Phase 2/3 trial of AXS-05 in agitation associated with Alzheimer’s disease, the ADVANCE-1 trial, will also be presented.
Below are the details of the presentation, which will be given by Cedric O’Gorman, MD, Senior Vice President, Clinical Development and Medical Affairs of Axsome:
Poster Presentation:
Title: AXS-05 (Dextromethorphan/Bupropion): An Innovative Treatment in Clinical Development for Agitation Associated with Alzheimer’s Disease
Poster Session: P2-01
Poster Number: P2-033
Date: Monday, July 23, 2018
Time: 9:30 AM – 4:15 PM Central Time
AXS-05 combines glutamatergic, monoaminergic, and anti-inflammatory mechanisms of action. The biological pathways targeted by these pharmacological actions have been implicated in a wide range of CNS disorders including depression, neuropsychiatric symptoms of Alzheimer’s disease, and nicotine dependence.
A copy of the poster presentation will be available shortly after the meeting on Axsome’s website at http://www.axsome.com.
About AXS-05
AXS-05 is a novel, oral, investigational medicine under development for the treatment of central nervous system (CNS) disorders. AXS-05 consists of bupropion and dextromethorphan and utilizes Axsome’s metabolic inhibition technology. Dextromethorphan is an NMDA receptor antagonist, sigma-1 receptor agonist, nicotinic acetylcholine receptor antagonist, and inhibitor of the serotonin and norepinephrine transporters. Bupropion serves to increase the bioavailability of dextromethorphan, and is a norepinephrine and dopamine reuptake inhibitor, and a nicotinic acetylcholine receptor antagonist. AXS-05 is not approved by the FDA.
About Axsome Therapeutics, Inc… Best
$AXSM long at $3.20 🙂 Best 🙂
$AXSM Form 4 6/19 http://archive.fast-edgar.com//20180620/A7AZC22C8Z22O2Z222942MZZGVTPZ2Y2DVA2/ Best
$IPIX > Innovation Pharmaceuticals Signs Drug Product Manufacturing Contract with CoreRx to Formulate and Package Brilacidin for Oral Mucositis in Sachet Form
BEVERLY, MA – June 17, 2018 (GLOBE NEWSWIRE) Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report the Company has signed a Drug Product manufacturing contract with CoreRx, a leading Contract Development Manufacturing Organization (CDMO), for formulating Brilacidin into granular form in unit dose sachets. Such drug product packaging in the form of sachets provides patients with a convenient, portable, quick-mixing “instant” Brilacidin oral rinse therapy.
Sachets are planned to be used in the continuing clinical evaluation of Brilacidin for the indication to decrease the incidence of Severe Oral Mucositis (SOM) (WHO Grade ≥ 3) in Head and Neck Cancer (HNC) patients receiving chemoradiation therapy.
The CoreRx agreement for Drug Product production aligns with one signed in April with another leading CDMO to, in parallel, bulk produce a commercial-grade supply of Brilacidin. Both of these manufacturing agreements serve to prepare for, and expedite, Brilacidin’s continued clinical development. Brilacidin is a defensin-mimetic drug candidate with unique immunomodulatory, anti-inflammatory, and antibacterial properties.
“CoreRx is pleased to have been selected by Innovation Pharmaceuticals for the development of Brilacidin sachets,” said Todd R. Daviau, President and CEO. “Having a sachet as a convenient oral therapy is long overdue in the treatment of oral mucositis, and we look forward to working with Innovation Pharmaceuticals to develop this new formulation and provide clinical trial supplies for this important indication.”
“Packaging Brilacidin in an easy-to-use sachet would likely substantially enhance its appeal and adoption among patients at risk for oral mucositis,” commented Arthur P. Bertolino, MD, PhD, MBA, President and Chief Medical Officer at Innovation Pharmaceuticals. “IV-based oral mucositis therapies present distinct challenges to patients already overwhelmed with the burden of cancer care—requiring visitation to a hospital or a doctor’s office, and up to an hour (or more) to administer the drug. Brilacidin packaged in a sachet, in contrast, allows patients the convenience of taking their medication whether they are at home or elsewhere. Sachets are an optimal way of delivering much-needed treatments to this substantial patient population in need of an effective and easy to administer therapy.”
“This agreement with CoreRx is yet another important milestone positioning Brilacidin as one of the most promising drug candidates in late-stage development for the prevention and treatment of oral mucositis,” said Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals. “CoreRx is now a valued contributor to advancing our Brilacidin development plan.”
About CoreRx Corporation
CoreRx is a Contract Development Manufacturing Organization (CDMO) with a focus on clinical phase drug product development, offering state of the art facilities to support supply chain needs throughout the entire clinical trial process. Integrated offerings provide comprehensive services for the development, manufacturing and testing of solid, liquid and semi-solid dosage forms, from pre-formulation work to final formulation development. More information is available at: http://www.corerxpharma.com.
… Best
$CLRB ow > Cellectar Reports 94% Reduction in Overall Tumor Volume in Waldenstrom Macroglobulinemia Patient in Phase 2 CLR 131 Clinical Study http://investor.cellectarbiosciences.com/news-releases/news-release-details/cellectar-reports-94-reduction-overall-tumor-volume-waldenstrom 🙂 Best2ALL! 🙂
$APTO ow > Insider Filing Browser https://ceo.ca/api/sedi/?symbol=APS&amount=&transaction=&insider= … #Best2You!
$MBRX Moleculin Expects to Meet FDA IND Filing Requirements for its Pancreatic Cancer Drug Candidate with Development Work in Australia https://ir.moleculin.com/press-releases/detail/94 Best
$CLRB > July 18, 2018 8:00 AM EDT
Cellectar Reports Positive Phase 2 Interim Data for CLR 131 in Relapsed/Refractory DLBCL Patients
http://investor.cellectarbiosciences.com/news-releases/news-release-details/cellectar-reports-positive-phase-2-interim-data-clr-131
$CLRB – So, Gr8Full! – Here’s a question: why on the 17th at opening did $CLRB virtually double its price to $11.24 and then slowly deflate all during the day? Single large purchase or ? Just curious …
$CLRB long > I was not watching the tape at the time, Allison. There are several minutes on the 1 minute chart with volume exceeding 150K. #Best2YouAlwayz!
$CLRB, didn’t they just do a reverse split? Best to all….John
$CLRB > Cellectar Reports Positive Phase 2 Interim Data for CLR 131 in Relapsed/Refractory DLBCL Patients http://investor.cellectarbiosciences.com/news-releases/news-release-details/cellectar-reports-positive-phase-2-interim-data-clr-131
$TEUM > Pareteum Awarded $10 Million Contract from Asian Mobile and Cryptocurrency Enterprise
Utilizing Pareteum’s Insights Engine to Increase Subscriber Base
NEW YORK, NEW YORK – PRNewswire – July 18, 2018 – Pareteum Corporation (NYSE American: TEUM), (“Pareteum” or the “Company”), the rapidly growing Global Cloud Software company, delivering award winning mobile enablement solutions, announced today that an established provider of multi-level marketing plans has chosen the Pareteum Global Cloud Service Platform to extend their connectivity options.
Pareteum’s Global Cloud Service Platform (GCSP), paired with its Insights Engine and Ethereum Blockchain application capabilities, will enable our newest customer to expand their services and reach larger target audiences. Our customer currently offers multi-level marketing and advertising-sponsored mobile services to subscribers. Those subscribers receive remuneration in the form of cryptocurrency settlements that can be applied toward the purchase of added connectivity and usage for their devices. Pareteum’s Insights Engine will collect, analyze, and, via Predictive Analytics, deliver actionable intelligence and reports to more effectively target new subscribers. Pareteum’s GCSP will also provide software services to meter, rate, provision new customers, deliver bills, and collect payments, as an integrated solution for our customer’s business operations.
“This established Currency Settlement Provider has chosen Pareteum because of our ability to deliver a solution that will enable them to expand their marketing operations and customer base, without a large cash investment. Utilizing Pareteum’s Insights Engine in conjunction with our GCSP will allow the customer to manage all their service offerings from a single point of delivery,” commented Vic Bozzo, Chief Executive Officer of Pareteum.
Hal Turner, Pareteum’s Executive Chairman and Principal Executive Officer, said, “Pareteum consistently executes on promises made by simply doing what we said we would do. Our new client will now use our artificial intelligent Insights Engine, along with our advanced, software based, computer API applications, for payment services that utilize blockchain, as well as digital payments and settlements. This leading-edge software solution, tailored for the specific uses of our client, means trustful and secure payment system transactions among advertisers, subscribers and our client. We are very pleased to bring reality to trends and concepts for our clients. We see many more steps ahead, and we are expecting to execute ‘BIG and Globally’ for all who need this software solution and our API’s!”…
#Best2You!
$CLRB > Corporate Presentation Jul 2018 http://investor.cellectarbiosciences.com/node/11676/html #Best2You!